New Delhi: Pharmaceuticals firm Lupin has received approval from the US Food and Drug Administration (FDA) to market its Desoximetasone ointment, used for providing relief from inflammation and itching in a skin disease.
The company has received final approval to market its Desoximetasone ointment USP, 0.05 per cent from the US health regulator, Lupin said in a filing to the BSE.
The product filing is from the company's Pithampur manufacturing facility, it added.
The Mumbai-based company's product is the generic version of Taro Pharms North's Topicort ointment in the same strength.
As per IMS, MAT September 2016 sales data, Topicort had US sales of $12.1 million, Lupin said.
The ointment is "indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses," it added.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
